Dicarboxylic acids and derivatives

Medchemexpress LLC N-(2-(1H-indol-3-yl)ethyl)-5-(5-fluoropyridin-3-yl)-3-methylpyrazolo[1,5-a]pyrimidin-7-amine | 2247950-73-6 | 98.0% | C22H19FN6 | 10MG

Small and Specialty Supplier Partner
Small and/or specialty supplier based on Federal laws and SBA requirements.
Learn More

KYN-101 is a small-molecule, selective, orally active antagonist of the aryl hydrocarbon receptor (AHR) supplied for laboratory research. It reduces CYP1A1 mRNA expression and has demonstrated anti-cancer activity in preclinical studies, making it suitable for mechanistic studies of AHR signaling and oncology research.

• Selective AHR inhibition with reported nanomolar potency.
• Orally active in preclinical models.
• Reduces CYP1A1 mRNA expression in cellular assays.
• Useful for mechanistic studies of AHR signaling and cancer biology.
• Available as solid and ready-to-use DMSO solutions for assay setup.
• High purity suitable for research applications.

Medchemexpress LLC N-(2-(1H-indol-3-yl)ethyl)-5-(5-fluoropyridin-3-yl)-3-methylpyrazolo[1,5-a]pyrimidin-7-amine | 2247950-73-6 | 98.0% | 386.42 g/mol | C22H19FN6 | 5 MG

Small and Specialty Supplier Partner
Small and/or specialty supplier based on Federal laws and SBA requirements.
Learn More

KYN-101 is a potent, selective, orally active aryl hydrocarbon receptor (AHR) inhibitor used in research. It reduces CYP1A1 mRNA expression and has demonstrated anti-cancer activity in preclinical studies. Supplied as a small-quantity research compound with accompanying quality documentation.

• Potent, selective aryl hydrocarbon receptor (AHR) inhibitor.
• Orally active in preclinical models.
• Decreases CYP1A1 mRNA expression in cellular assays.
• Demonstrates anti-cancer activity in preclinical studies.
• Supplied as a small research quantity (e.g., 5 mg) with COA and datasheet.
• High purity (approximately 98.0%).
• For research use only; not for human or clinical use.